Navigation Links
Bayer CropScience Looks to the Future of Farming at 2013 Farm Progress Show
Date:8/29/2013

DECATUR, Ill. (PRWEB) August 29, 2013

Executives from Bayer CropScience today addressed the need for a New Revolution in Agriculture to tackle critical challenges the agricultural industry is facing now and into the future.

“Food security is critical to the health and well-being of our world. With a fast-growing world to feed and clothe, Bayer is leading a New Revolution in Agriculture, one that is grounded in innovation and collaboration,” said Jim Blome, president and CEO of Bayer CropScience LP. “Bayer is developing solutions to help growers worldwide address urgent issues, including water scarcity, herbicide-resistant weeds and the need to maintain and increase crop yields.”

Blome spoke at the 2013 Farm Progress Show in Decatur, Ill., where the company’s booth “One World to Grow On,” highlights solutions that help growers achieve success, from planning and planting through harvest. The interactive exhibit identifies four pivotal decision-making times in the growing season?Plan for Success, Establish a Healthy Crop, Maintain the Potential and Successful Harvest—and provides technical information on flagship brands, as well as tips for producers to maximize decisions at each stage.

The company’s integrated solutions are the result of innovation both in the laboratory and the field, and reflect Bayer CropScience’s investment in traditional chemistry, biologics and seeds, he said.

Leading a New Revolution in Agriculture
As Bayer celebrates 150 years of Science For A Better Life, it is propelling the future of farming through focused research, as well as cultivating ideas and ans
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
2. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
3. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
4. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
5. Bayer Bee Care Center Helps Solve Bee Health’s Toughest Challenges
6. Growers Choose the Bayer CropScience LibertyLinkSystem for Yield and Performance
7. Bayer CropScience Provides a Glimpse of SeedGrowth™ Innovation
8. Bayer CropScience Launches Third Annual Young Farmer Sustainability Award Program
9. Bayer CropScience Hosts Inaugural Vegetable Future Forum in Monheim
10. Bayer CropScience Announces Registration for use of Alion on Grapes in California
11. Bayer CropScience Purchases Land Adjacent to its Research Triangle Park Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 “Nature has developed, very cleverly, ... we desire in optical design,” said Joseph Shaw, director ... “As we explore surfaces and structures at the nanoscale, ... presented in San Diego in August during a conference ... ” chaired by Shaw and Rongguang Liang of the ...
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... September 16, 2014 CIRTEC Medical Systems’ ... Highley as CEO of CIRTEC. , “I am ... for the Company.” noted Brian Highley. “The company has ... sustaining strong organic growth over the past two years. ... continuing to improve and expand the services Cirtec offers ...
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the leading ... products to hospitals, physician office laboratories and alternate ... October 1, 2014, it will serve as Siemens ... market segments and as a semi-exclusive sales distributor ... contiguous United States . LABSCO ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... -- As open enrollment season approaches, U.S. employees will soon ... benefits. According to Aon Hewitt , the global ... plc (NYSE: AON ), employees will ... managing their health care decisions. This increased responsibility makes ... how they can make the most of the programs ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7
... "crack baby" hysteria of the 1980s was greatly ... but disabling cognitive impairments -- attention deficits, learning ... study by investigators at the Vanderbilt Kennedy Center ... the long-term behavioral and neurological problems associated with ...
... especially those that are hydrophobic or water-repellant, to tumors ... develop innovative delivery systems that keep these drugs intact ... University at Buffalo’s Institute for Lasers, Photonics and Biophotonics ... solution in which the delivery system is the drug ...
... Researchers have linked a structural protein called nestin to ... new biomarker that could lead to earlier detection and ... of Cancer Research, researchers from Dartmouth Medical School demonstrate ... basal epithelial breast tumors, a highly aggressive cancer with ...
Cached Biology News:Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3No carrier necessary: This drug delivers itself 2Selective marker found to indicate aggressive form of breast cancer 2
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Fragment is a genetically engineered Klenow polymerase in ... been removed, leaving only the 5 to 3 ... Exo- Klenow Fragment the enzyme of choice for ... the random primed method, and for DNA sequencing ...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
Biology Products: